Identification and Evaluation of biomarkers to detect bladder cancer
978-3-659-58940-9
3659589403
252
2015-02-13
55,90 €
eng
https://images.our-assets.com/cover/230x230/9783659589409.jpg
https://images.our-assets.com/fullcover/230x230/9783659589409.jpg
https://images.our-assets.com/cover/2000x/9783659589409.jpg
https://images.our-assets.com/fullcover/2000x/9783659589409.jpg
Urinary Bladder Cancer (UBC) is the 5th most common cancer in the West. Continuous efforts have been made to develop non-invasive urine-based biomarkers with high sensitivity and specificity that would improve patients’ quality of life, costs and lower the number of cystoscopies. This can then be utilized as part of a multi-biomarker panel to develop a urine test for UBC diagnosis as a single marker is unable to replace current diagnostic invasive tools. Using a (LC-MS/MS) proteomic approach, 8 UBC and 1 normal bladder cell secretomes were analysed to identify secreted proteins that can be potential candidate biomarkers. phorbol 12-myristate 13-acetate (PMA; PKC activator was used to treat whole secretomes and investigate all proteins released by cells whereas secretomes that were treated with the broad-spectrum inhibitor, Marimastat underwent ultracentrifugation to focus on proteins being shedded. Protein quantification was based upon stable isotope labelling by peptide demethylation. Two methods were utilized to select candidate biomarkers: Human Protein Atlas and Ingenuity Pathway Analysis. EpCAM biology was also examined to see the effects of PMA and Marimastat on its ectodomain.
https://www.morebooks.de/books/it/published_by/lap-lambert-academic-publishing/47/products
Medicina
https://www.morebooks.de/store/it/book/identification-and-evaluation-of-biomarkers-to-detect-bladder-cancer/isbn/978-3-659-58940-9